Skip to main content
NCBI home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2009 Jan;6(1):43–52. doi: 10.1016/j.nurt.2008.10.032

Multifunctional actions of approved and candidate stroke drugs

Jens Minnerup 1,✉, Wolf-Rüdiger Schäbitz 1
PMCID: PMC5084255  PMID: 19110198

Summary

Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In this review, we describe the mechanisms of action of agents approved for secondary prevention of ischemic stroke, such as antiplatelet, antihypertensive, and lipid-lowering drugs. These drugs exhibit considerable properties beyond their classical mechanisms, including neuroprotective and neuroregenerative properties. In addition, candidate stroke drugs currently studied in clinical phase III trials are described. Among these, albumin, hematopoietic growth factors, and citicoline have been identified as promising agents with multiple mechanisms. These drugs offer hope that additional treatment options for the acute phase after a stroke will become available in the near future.

Key Words: Stroke, drug therapy, mechanisms, neuroprotection, neuroregeneration

Contributor Information

Jens Minnerup, Email: minnerup@uni-muenster.de.

Wolf-Rüdiger Schäbitz, Email: schabitz@uni-muenster.de.

References

  • 1.Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482–2494. doi: 10.1056/NEJMra071014. [DOI] [PubMed] [Google Scholar]
  • 2.Savage B, Cattaneo M, Ruggeri ZM. Mechanisms of platelet aggregation. Curr Opin Hematol. 2001;8:270–276. doi: 10.1097/00062752-200109000-00002. [DOI] [PubMed] [Google Scholar]
  • 3.Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227–1234. doi: 10.1038/nm1102-1227. [DOI] [PubMed] [Google Scholar]
  • 4.European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis. 2008;25:457–507. doi: 10.1159/000131083. [DOI] [PubMed] [Google Scholar]
  • 5.Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J. 1956;78:213–215. [PubMed] [Google Scholar]
  • 6.The Dutch TIA Trial Study Group A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–1266. doi: 10.1056/NEJM199110313251801. [DOI] [PubMed] [Google Scholar]
  • 7.International Stroke Trial Collaborative Group The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet. 1997;349:1569–1581. doi: 10.1016/S0140-6736(97)04011-7. [DOI] [PubMed] [Google Scholar]
  • 8.Patrono C, García Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373–2383. doi: 10.1056/NEJMra052717. [DOI] [PubMed] [Google Scholar]
  • 9.De Cristóbal J, Moro MA, Dávalos, et al. Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in rats. J Neurochem. 2001;79:456–459. doi: 10.1046/j.1471-4159.2001.00600.x. [DOI] [PubMed] [Google Scholar]
  • 10.Berger C, Xia F, Schäbitz WR, Schwab S, Grau A. High-dose aspirin is neuroprotective in a rat focal ischemia model. Brain Res. 2004;998:237–242. doi: 10.1016/j.brainres.2003.11.049. [DOI] [PubMed] [Google Scholar]
  • 11.Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection by aspirin and sodium salicylate through blockade of NF-κB activation. Science. 1996;274:1383–1385. doi: 10.1126/science.274.5291.1383. [DOI] [PubMed] [Google Scholar]
  • 12.Berger C, Stauder A, Xia F, Sommer C, Schwab S. Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia. Exp Neurol. 2008;210:543–548. doi: 10.1016/j.expneurol.2007.12.002. [DOI] [PubMed] [Google Scholar]
  • 13.Zheng Z, Schwab S, Grau A, Berger C. Neuroprotection by early and delayed treatment of acute stroke with high dose aspirin. Brain Res. 2007;1186:275–280. doi: 10.1016/j.brainres.2007.10.029. [DOI] [PubMed] [Google Scholar]
  • 14.Whitehead SN, Bayona NA, Cheng G, Allen GV, Hachinski VC, Cechetto DF. Effects of triflusal and aspirin in a rat model of cerebral ischemia. Stroke. 2007;38:381–387. doi: 10.1161/01.STR.0000254464.05561.72. [DOI] [PubMed] [Google Scholar]
  • 15.Khayyam N, Thavendiranathan P, Carmichael FJ, Kus B, Jay V, Burnham WM. Neuroprotective effects of acetylsalicylic acid in an animal model of focal brain ischemia. Neuroreport. 1999;10:371–374. doi: 10.1097/00001756-199902050-00029. [DOI] [PubMed] [Google Scholar]
  • 16.Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature. 1998;391:281–285. doi: 10.1038/34651. [DOI] [PubMed] [Google Scholar]
  • 17.Crisanti P, Leon A, Lim DM, Omri B. Aspirin prevention of NMDA-induced neuronal death by direct protein kinase Cζ inhibition. J Neurochem. 2005;93:1587–1593. doi: 10.1111/j.1471-4159.2005.03157.x. [DOI] [PubMed] [Google Scholar]
  • 18.Maharaj H, Maharaj DS, Daya S. Acetylsalicylic acid and acetaminophen protect against oxidative neurotoxicity. Metab Brain Dis. 2006;21:189–199. doi: 10.1007/s11011-006-9012-7. [DOI] [PubMed] [Google Scholar]
  • 19.Riepe MW, Kasischke K, Raupach A. Acetylsalicylic acid increases tolerance against hypoxic and chemical hypoxia. Stroke. 1997;28:2006–2011. doi: 10.1161/01.str.28.10.2006. [DOI] [PubMed] [Google Scholar]
  • 20.Sanossian N, Saver JL, Rajajee V, et al. Premorbid antiplatelet use and ischemic stroke outcomes. Neurology. 2006;66:319–323. doi: 10.1212/01.wnl.0000195889.05792.f1. [DOI] [PubMed] [Google Scholar]
  • 21.Wilterdink JL, Bendixen B, Adams HP, Woolson RF, Clarke WR, Hansen MD. Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST) Stroke. 2001;32:2836–2840. doi: 10.1161/hs1201.099384. [DOI] [PubMed] [Google Scholar]
  • 22.Lindsberg PJ, Grau AJ. Inflammation and infections as risk factors for ischemic stroke. Stroke. 2003;34:2518–2532. doi: 10.1161/01.STR.0000089015.51603.CC. [DOI] [PubMed] [Google Scholar]
  • 23.Kammersgaard LP, Jørgensen HS, Reith J, et al. Early infection and prognosis after acute stroke: the Copenhagen Stroke Study. J Stroke Cerebrovasc Dis. 2001;10:217–221. doi: 10.1053/jscd.2001.30366. [DOI] [PubMed] [Google Scholar]
  • 24.Paoletti R, Gotto AM, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(23):III20–III26. doi: 10.1161/01.CIR.0000131514.71167.2e. [DOI] [PubMed] [Google Scholar]
  • 25.Marquardt L, Ruf A, Mansmann U, et al. Inflammatory response after acute ischemic stroke. J Neurol Sci. 2005;236:65–71. doi: 10.1016/j.jns.2005.05.006. [DOI] [PubMed] [Google Scholar]
  • 26.Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979. doi: 10.1056/NEJM199704033361401. [DOI] [PubMed] [Google Scholar]
  • 27.Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study: 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1–13. doi: 10.1016/S0022-510X(96)00308-5. [DOI] [PubMed] [Google Scholar]
  • 28.Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial [Erratum in: Lancet 2007;369:274] Lancet. 2006;367:1665–1673. doi: 10.1016/S0140-6736(06)68734-5. [DOI] [PubMed] [Google Scholar]
  • 29.Gould KL, Westcott RJ, Albro PC, Hamilton GW. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilatation: II. Clinical methodology and feasibility. Am J Cardiol. 1978;41:279–287. doi: 10.1016/0002-9149(78)90166-2. [DOI] [PubMed] [Google Scholar]
  • 30.Ito H, Kinoshita T, Tamura Y, Yokoyama I, Iida H. Effect of intravenous dipyridamole on cerebral blood flow in humans: a PET study. Stroke. 1999;30:1616–1620. doi: 10.1161/01.str.30.8.1616. [DOI] [PubMed] [Google Scholar]
  • 31.Heistad DD, Marcus ML, Gourley JK, Busija DW. Effect of adenosine and dipyridamole on cerebral blood flow. Am J Physiol. 1981;240:H775–H780. doi: 10.1152/ajpheart.1981.240.5.H775. [DOI] [PubMed] [Google Scholar]
  • 32.Costantini V, Talpacci A, Bastiano ML, et al. Increased prostacyclin production from human veins by dipyridamole: an in vitro and ex vivo study. Biomed Biochim Acta. 1990;49:263–271. [PubMed] [Google Scholar]
  • 33.Neri Semeri GG, Masotti G, Poggesi L, Galanti G, Morettini A. Enhanced prostacyclin production by dipyridamole in man. Eur J Clin Pharmacol. 1981;21:9–15. doi: 10.1007/BF00609581. [DOI] [PubMed] [Google Scholar]
  • 34.Iuliano L, Pedersen JZ, Rotilio G, Ferro D, Violi F. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic Biol Med. 1995;18:239–247. doi: 10.1016/0891-5849(94)E0123-Z. [DOI] [PubMed] [Google Scholar]
  • 35.Iuliano L, Colavita AR, Camastra C, et al. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br J Pharmacol. 1996;119:1438–1446. doi: 10.1111/j.1476-5381.1996.tb16056.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Farinelli SE, Greene LA, Friedman WJ. Neuroprotective actions of dipyridamole on cultured CNS neurons. J Neurosci. 1998;18:5112–5123. doi: 10.1523/JNEUROSCI.18-14-05112.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Blake AD. Dipyridamole is neuroprotective for cultured rat embryonic cortical neurons. Biochem Biophys Res Commun. 2004;314:501–504. doi: 10.1016/j.bbrc.2003.12.115. [DOI] [PubMed] [Google Scholar]
  • 38.Aldandashi S, Noor R, Wang CX, Uddin G, Shuaib A. Combination treatment with dipyridamole, aspirin, and tPA in an embolic model of stroke in rats. Exp Neurol. 2007;205:563–568. doi: 10.1016/j.expneurol.2007.03.018. [DOI] [PubMed] [Google Scholar]
  • 39.Picano E, Abbracchio MP. European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation? Trends Pharmacol Sci. 1998;19:14–16. doi: 10.1016/S0165-6147(97)01148-6. [DOI] [PubMed] [Google Scholar]
  • 40.Weyrich AS, Denis MM, Kuhlmann-Eyre JR, et al. Dipyridamole selectively inhibits inflammatory gene expression in plateletmonocyte aggregates. Circulation. 2005;111:633–642. doi: 10.1161/01.CIR.0000154607.90506.45. [DOI] [PubMed] [Google Scholar]
  • 41.Tony RJ, O’Brien DM, Connell PM, Tomanek RJ. Dipyridamole-induced capillary growth in normal and hypertrophic hearts. Am J Physiol. 1992;262:H980–H986. doi: 10.1152/ajpheart.1992.262.4.H980. [DOI] [PubMed] [Google Scholar]
  • 42.CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet. 1996;348:1329–1339. doi: 10.1016/S0140-6736(96)09457-3. [DOI] [PubMed] [Google Scholar]
  • 43.Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008;359:1238–1251. doi: 10.1056/NEJMoa0805002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Foster CJ, Rosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001;107:1591–1598. doi: 10.1172/JCI12242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994;72:313–317. [PubMed] [Google Scholar]
  • 46.Herbert JM, Tissinier A, Defreyn G, Maffrand JP. Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation after arterial injury in rabbits. Arterioscler Thromb. 1993;13:1171–1179. doi: 10.1161/01.atv.13.8.1171. [DOI] [PubMed] [Google Scholar]
  • 47.Cortelekoglu T, Bozkurt AK, Ustundag N, Koksal C, Sayin AG. The effects of clopidogrel and calcium dobesilate on intimal hyperplasia following vascular injury. Acta Chir Belg. 2006;106:206–210. doi: 10.1080/00015458.2006.11679872. [DOI] [PubMed] [Google Scholar]
  • 48.Yang LH, Fareed J. Vasomodulatory action of clopidogrel and ticlopidine. Thromb Res. 1997;86:479–491. doi: 10.1016/S0049-3848(97)00097-2. [DOI] [PubMed] [Google Scholar]
  • 49.Huber R, Riepe MW. Improved posthypoxic recovery in vitro on treatment with drugs used for secondary stroke prevention. Neuropharmacology. 2005;48:558–565. doi: 10.1016/j.neuropharm.2004.12.002. [DOI] [PubMed] [Google Scholar]
  • 50.PATS Collaborating Group Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J (Engl) 1995;108:710–717. [PubMed] [Google Scholar]
  • 51.Schrader J, Lüders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES) Stroke. 2005;36:1218–1226. doi: 10.1161/01.STR.0000166048.35740.a9. [DOI] [PubMed] [Google Scholar]
  • 52.Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension study. Hypertension. 2005;45:46–52. doi: 10.1161/01.HYP.0000151324.05355.1c. [DOI] [PubMed] [Google Scholar]
  • 53.Toffelmire EB, Slater K, Corvol P, Menard J, Schambelan M. Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans: studies using a direct immunoradiometric assay. J Clin Invest. 1989;83:679–687. doi: 10.1172/JCI113932. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Naftilan AJ, Zuo WM, Inglefinger J, Ryan TJ, Pratt RE, Dzau VJ. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest. 1991;87:1300–1311. doi: 10.1172/JCI115133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Griendling KK, Lassègue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu Rev Pharmacol Toxicol. 1996;36:281–306. doi: 10.1146/annurev.pharmtox.36.1.281. [DOI] [PubMed] [Google Scholar]
  • 56.Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996;334:1649–1654. doi: 10.1056/NEJM199606203342507. [DOI] [PubMed] [Google Scholar]
  • 57.Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355:637–645. doi: 10.1016/S0140-6736(99)10365-9. [DOI] [PubMed] [Google Scholar]
  • 58.Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke. 1999;30:2391–2398. doi: 10.1161/01.str.30.11.2391. [DOI] [PubMed] [Google Scholar]
  • 59.Lu Q, Zhu YZ, Wong PT. Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats. Neuroreport. 2005;16:1963–1967. doi: 10.1097/01.wnr.0000187636.13147.cd. [DOI] [PubMed] [Google Scholar]
  • 60.Schmerbach K, Schefe JH, Krikov M, et al. Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. Brain Res. 2008;1208:225–233. doi: 10.1016/j.brainres.2008.02.032. [DOI] [PubMed] [Google Scholar]
  • 61.Hosomi N, Nishiyama A, Ban CR, et al. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience. 2005;134:225–231. doi: 10.1016/j.neuroscience.2005.03.054. [DOI] [PubMed] [Google Scholar]
  • 62.Polidori C, Ciccocioppo R, Pompei P, Cirillo R, Massi M. Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats. Eur J Pharmacol. 1996;307:259–267. doi: 10.1016/0014-2999(96)00270-1. [DOI] [PubMed] [Google Scholar]
  • 63.Bui JD, Kimura B, Phillips MI. Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier. Eur J Pharmacol. 1992;219:147–151. doi: 10.1016/0014-2999(92)90593-S. [DOI] [PubMed] [Google Scholar]
  • 64.Krikov M, Thone-Reineke C, Müller S, Villringer A, Unger T. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens. 2008;26:544–552. doi: 10.1097/HJH.0b013e3282f2dac9. [DOI] [PubMed] [Google Scholar]
  • 65.Liu H, Kitazato KT, Uno M, et al. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies. J Hypertens. 2008;26:1435–1445. doi: 10.1097/HJH.0b013e3283013b6e. [DOI] [PubMed] [Google Scholar]
  • 66.Wassmann S, Czech T, van Eickels M, Fleming I, Bohm M, Nickenig G. Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation. 2004;110:3062–3067. doi: 10.1161/01.CIR.0000137970.47771.AF. [DOI] [PubMed] [Google Scholar]
  • 67.Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586–1593. doi: 10.1161/01.cir.101.13.1586. [DOI] [PubMed] [Google Scholar]
  • 68.Oubiña MP, de Las Heras N, Vázquez-Pérez S, et al. Valsartan improves fibrinolytic balance in atherosclerotic rabbits. J Hypertens. 2002;20:303–310. doi: 10.1097/00004872-200202000-00021. [DOI] [PubMed] [Google Scholar]
  • 69.Wolf SC, Sauter G, Rodemann HP, Risler T, Brehm BR. Influence of growth factors on the proliferation of vascular smooth muscle cells isolated from subtotally nephrectomized rats after endothelin or angiotensin II antagonism. Nephrol Dial Transplant. 2005;20:312–318. doi: 10.1093/ndt/gfh606. [DOI] [PubMed] [Google Scholar]
  • 70.Daran DE, Weiss D, Zhang Y, Griendling KK, Taylor WR. Differential effects of ATI receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis. 2007;195:39–47. doi: 10.1016/j.atherosclerosis.2006.11.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Tsuda M, Iwai M, Li JM, et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension. 2005;45:545–551. doi: 10.1161/01.HYP.0000157409.88971.fc. [DOI] [PubMed] [Google Scholar]
  • 72.Piechowski-Jozwiak B, Bogousslavsky J. Cholesterol as a risk factor for stroke: the fugitive? Stroke. 2004;35:1523–1524. doi: 10.1161/01.STR.0000130460.09807.ec. [DOI] [PubMed] [Google Scholar]
  • 73.Thrift AG. Cholesterol is associated with stroke, but is not a risk factor. Stroke. 2004;35:1524–1525. doi: 10.1161/01.STR.0000128590.48495.02. [DOI] [PubMed] [Google Scholar]
  • 74.Amarenco P, Bogousslavsky J, Callahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–559. doi: 10.1056/NEJMoa061894. [DOI] [PubMed] [Google Scholar]
  • 75.Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch Intern Med. 2003;163:669–676. doi: 10.1001/archinte.163.6.669. [DOI] [PubMed] [Google Scholar]
  • 76.Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;292:1160–1164. doi: 10.1126/science.1059344. [DOI] [PubMed] [Google Scholar]
  • 77.Schartl M, Bocksch W, Koschyk DH, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation. 2001;104:387–392. doi: 10.1161/hc2901.093188. [DOI] [PubMed] [Google Scholar]
  • 78.Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–933. doi: 10.1161/01.cir.103.7.926. [DOI] [PubMed] [Google Scholar]
  • 79.Knapp AC, Huang J, Starling G, Kiener PA. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. Atherosclerosis. 2000;152:217–227. doi: 10.1016/S0021-9150(99)00462-1. [DOI] [PubMed] [Google Scholar]
  • 80.Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of lowdensity lipoprotein cholesterol reduction. Circulation. 2002;106:1447–1452. doi: 10.1161/01.CIR.0000029743.68247.31. [DOI] [PubMed] [Google Scholar]
  • 81.Weitz-Schmidt G, Weizenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 2001;7:687–692. doi: 10.1038/89058. [DOI] [PubMed] [Google Scholar]
  • 82.Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6:1399–1402. doi: 10.1038/82219. [DOI] [PubMed] [Google Scholar]
  • 83.Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426–431. doi: 10.1161/01.CIR.0000080895.05158.8B. [DOI] [PubMed] [Google Scholar]
  • 84.Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol. 2003;23:322–327. doi: 10.1161/01.ATV.0000044458.23905.3B. [DOI] [PubMed] [Google Scholar]
  • 85.Asahi M, Huang Z, Thomas S, et al. Protective effects of statins involving both eNOS and tPA in focal cerebral ischemia. J Cereb Blood Flow Metab. 2005;25:722–729. doi: 10.1038/sj.jcbfm.9600070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Amin-Hanjani S, Stagliano NE, Yamada M, Huang PL, Liao JK, Moskowitz MA. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980–986. doi: 10.1161/01.str.32.4.980. [DOI] [PubMed] [Google Scholar]
  • 87.Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem. 1998;273:24266–24271. doi: 10.1074/jbc.273.37.24266. [DOI] [PubMed] [Google Scholar]
  • 88.Kureishi Y, Luo Z, Shiojima I, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6:1004–1010. doi: 10.1038/79510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Ponce J, de la Ossa NP, Hurtado O, et al. Simvastatin reduces the association of NMDA receptors to lipid rafts: a cholesterol-mediated effect in neuroprotection. Stroke. 2008;39:1269–1275. doi: 10.1161/STROKEAHA.107.498923. [DOI] [PubMed] [Google Scholar]
  • 90.Zheng Z, Chen B. Effects of pravastatin on neuroprotection and neurogenesis after cerebral ischemia in rats. Neurosci Bull. 2007;23:189–197. [PubMed] [Google Scholar]
  • 91.Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743–751. doi: 10.1002/ana.10555. [DOI] [PubMed] [Google Scholar]
  • 92.Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256. doi: 10.1056/NEJMoa040232. [DOI] [PubMed] [Google Scholar]
  • 93.Belayev L, Khoutorova L, Belayev A, et al. Delayed post-ischemic albumin treatment neither improves nor worsens the outcome of transient focal cerebral ischemia in rats. Brain Res. 2004;998:243–246. doi: 10.1016/j.brainres.2003.11.015. [DOI] [PubMed] [Google Scholar]
  • 94.Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 2001;32:553–560. doi: 10.1161/01.str.32.2.553. [DOI] [PubMed] [Google Scholar]
  • 95.Belayev L, Pinard E, Nallet H, et al. Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses. Stroke. 2002;33:1077–1084. doi: 10.1161/hs0402.105555. [DOI] [PubMed] [Google Scholar]
  • 96.Park HP, Nimmagadda A, DeFazio RA, Busto R, Prado R, Ginsberg MD. Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study. Stroke. 2008;39:1556–1562. doi: 10.1161/STROKEAHA.107.502195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Liu Y, Belayev L, Zhao W, Busto R, Belayev A, Ginsberg MD. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. Eur J Pharmacol. 2001;428:193–201. doi: 10.1016/S0014-2999(01)01255-9. [DOI] [PubMed] [Google Scholar]
  • 98.Ginsberg MD. Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke. 2007;38:1967–1972. doi: 10.1161/STROKEAHA.106.479170. [DOI] [PubMed] [Google Scholar]
  • 99.Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke: I. Physiological responses and safety results. Stroke. 2006;37:2100–2106. doi: 10.1161/01.STR.0000231388.72646.05. [DOI] [PubMed] [Google Scholar]
  • 100.Palesch YY, Hill MD, Ryckborst KJ, Tamariz D, Ginsberg MD. The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke: II. neurologic outcome and efficacy analysis. Stroke. 2006;37:2107–2114. doi: 10.1161/01.STR.0000231389.34701.b5. [DOI] [PubMed] [Google Scholar]
  • 101.Matsui T, Sinyama H, Asano T. Beneficial effect of prolonged administration of albumin on ischemic cerebral edema and infarction after occlusion of middle cerebral artery in rats. Neurosurgery. 1993;33:293–300. doi: 10.1227/00006123-199308000-00017. [DOI] [PubMed] [Google Scholar]
  • 102.Nimmagadda A, Park HP, Prado R, Ginsberg MD. Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study. Stroke. 2008;39:198–204. doi: 10.1161/STROKEAHA.107.495598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Rodriguez de Turco EB, Belayev L, Liu Y, et al. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem. 2002;83:515–524. doi: 10.1046/j.1471-4159.2002.01121.x. [DOI] [PubMed] [Google Scholar]
  • 104.Belayev L, Marcheselli VL, Khoutorova L, et al. Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke. 2005;36:118–123. doi: 10.1161/01.STR.0000149620.74770.2e. [DOI] [PubMed] [Google Scholar]
  • 105.Parkkinen J, Ojala P, Niiranen J, Jolkkonen J. Molecular mechanisms underlying neuroprotective effects of albumin after ischemic stroke. Stroke. 2007;38:255–255. doi: 10.1161/01.STR.0000254506.06583.2d. [DOI] [PubMed] [Google Scholar]
  • 106.Frampton JE, Lee CR, Faulds D. Filgrastim: a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs. 1994;48:731–760. doi: 10.2165/00003495-199448050-00007. [DOI] [PubMed] [Google Scholar]
  • 107.Schneider A, Krüger C, Steigleder T, et al. The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest. 2005;115:2083–2098. doi: 10.1172/JCI23559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Komine-Kobayashi M, Zhang N, Liu M, et al. Neuroprotective effect of recombinant human granulocyte colony-stimulating factor in transient focal ischemia of mice. J Cereb Blood Flow Metab. 2006;26:402–413. doi: 10.1038/sj.jcbfm.9600195. [DOI] [PubMed] [Google Scholar]
  • 109.Lee ST, Chu K, Jung KH, et al. Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res. 2005;1058:120–128. doi: 10.1016/j.brainres.2005.07.076. [DOI] [PubMed] [Google Scholar]
  • 110.Gibson CL, Jones NC, Prior MJ, Bath PM, Murphy SP. G-CSF suppresses edema formation and reduces interleukin-lβ expression after cerebral ischemia in mice. J Neuropathol Exp Neurol. 2005;64:763–769. doi: 10.1097/01.jnen.0000179196.10032.dd. [DOI] [PubMed] [Google Scholar]
  • 111.Schäbitz WR, Kollmar R, Schwaninger M, et al. Neuroprotective effect of granulocyte colony-stimulating factor after focal cerebral ischemia. Stroke. 2003;34:745–751. doi: 10.1161/01.STR.0000057814.70180.17. [DOI] [PubMed] [Google Scholar]
  • 112.Minnerup J, Heidrich J, Wellmann J, Rogalewski A, Schneider A, Schäbitz WR. Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke. 2008;39:1855–1861. doi: 10.1161/STROKEAHA.107.506816. [DOI] [PubMed] [Google Scholar]
  • 113.Bath PM, Sprigg N. Colony stimulating factors (including erythropoietin, granulocyte colony stimulating factor and analogues) for stroke. Cochrane Database Syst Rev 2007;(2):CD005207. [DOI] [PubMed]
  • 114.Schäbitz WR, Laage R, Schwab S, et al. AX 200 (G-CSF) for the treatment of acute ischemic stroke (AXIS). 17th European Stroke Conference, Nice, France, May 13–16, 2008. Abstracts. Basel: Karger, 2008:62.
  • 115.Härtung T, Von Aulock S, Schneider C, Faist E. How to leverage an endogenous immune defense mechanism: the example of granulocyte colony-stimulating factor. Crit Care Med. 2003;31:S65–S75. doi: 10.1097/00003246-200301001-00010. [DOI] [PubMed] [Google Scholar]
  • 116.Glaspy J, Beguin Y. Anaemia management strategies: optimising treatment using epoetin β (NeoRecormon) Oncology. 2005;69(Suppl 2):8–16. doi: 10.1159/000088283. [DOI] [PubMed] [Google Scholar]
  • 117.Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35:1732–1737. doi: 10.1161/01.STR.0000132196.49028.a4. [DOI] [PubMed] [Google Scholar]
  • 118.Villa P, Bigini P, Mennini T, et al. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med. 2003;198:971–975. doi: 10.1084/jem.20021067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002;8:495–505. [PMC free article] [PubMed] [Google Scholar]
  • 120.Sirén AL, Knerlich F, Poser W, Gleiter CH, Brück W, Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 2001;101:271–276. doi: 10.1007/s004010000297. [DOI] [PubMed] [Google Scholar]
  • 121.Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101:14907–14912. doi: 10.1073/pnas.0406491101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Ruscher K, Freyer D, Karsch M, et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci. 2002;22:10291–10301. doi: 10.1523/JNEUROSCI.22-23-10291.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Li Y, Lu Z, Keogh CL, Yu SP, Wei L. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab. 2007;27:1043–1054. doi: 10.1038/sj.jcbfm.9600417. [DOI] [PubMed] [Google Scholar]
  • 124.Sun Y, Calvert JW, Zhang JH. Neonatal hypoxia/ischemia is associated with decreased inflammatory mediators after erythropoietin administration. Stroke. 2005;36:1672–1678. doi: 10.1161/01.STR.0000173406.04891.8c. [DOI] [PubMed] [Google Scholar]
  • 125.Dávalos A, Castillo J, Alvarez-Sabín J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33:2850–2857. doi: 10.1161/01.STR.0000038691.03334.71. [DOI] [PubMed] [Google Scholar]
  • 126.Agut J, Font E, Sacristán A, Ortiz JA. Radioactivity incorporation into different cerebral phospholipids after oral administration of 14C methyl CDP-choline. Arzneimittelforschung. 1983;33:1048–1050. [PubMed] [Google Scholar]
  • 127.Adibhatla RM, Hatcher JF, Larsen EC, Chen X, Sun D, Tsao FH. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke. J Biol Chem. 2006;281:6718–6725. doi: 10.1074/jbc.M512112200. [DOI] [PubMed] [Google Scholar]
  • 128.Adibhatla RM, Hatcher JF, Dempsey RJ. Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke. 2001;32:2376–2381. doi: 10.1161/hs1001.096010. [DOI] [PubMed] [Google Scholar]
  • 129.Yen CL, Mar MH, Zeisel SH. Choline deficiency-induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase. FASEB J. 1999;13:135–142. [PubMed] [Google Scholar]
  • 130.Kakihana M, Fukuda N, Suno M, Nagaoka A. Effects of CDP-choline on neurologic deficits and cerebral glucose metabolism in a rat model of cerebral ischemia. Stroke. 1988;19:217–222. doi: 10.1161/01.str.19.2.217. [DOI] [PubMed] [Google Scholar]
  • 131.Fiesta M, Puglisi G, Di Giacomo C, Russo A. Liposomes as in-vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion. J Pharm Pharmacol. 1994;46:974–981. doi: 10.1111/j.2042-7158.1994.tb03252.x. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES